The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Background The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who were...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer Vol. 124; no. 21; pp. 4241 - 4247
Main Authors:	DuBois, Steven G., Laetsch, Theodore W., Federman, Noah, Turpin, Brian K., Albert, Catherine M., Nagasubramanian, Ramamoorthy, Anderson, Megan E., Davis, Jessica L., Qamoos, Hope E., Reynolds, Mark E., Cruickshank, Scott, Cox, Michael C., Hawkins, Douglas S., Mascarenhas, Leo, Pappo, Alberto S.
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.11.2018 John Wiley and Sons Inc
Subjects:	Children Complications Enzyme inhibitors Evaluation Fibrosarcoma infantile fibrosarcoma Inhibitors larotrectinib local control Morbidity neurotrophic receptor tyrosine kinase (NTRK) Oncology Original Patients pediatric Pediatrics Sarcoma Solid tumors Surgery Therapy Tropomyosin tropomyosin receptor kinase (TRK) fusion Tumors Wound healing larotrectinib sarcoma tropomyosin receptor kinase (TRK) fusion local control neurotrophic receptor tyrosine kinase (NTRK) infantile fibrosarcoma pediatric surgery
ISSN:	0008-543X, 1097-0142, 1097-0142
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!